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a control diet with minimal IF (low IF) or an HIF diet. Each dietary group was further
subdivided into groups receiving either water or Se at a dose of 3mg Se/kg bodyweight daily,
as Se-methylselenocysteine (SMSC). After 5 months, mice receiving SMSC had elevated
fasting glucose (P < .05) and a tendency for glucose intolerance (P = .08). The increase in
dietary IF did not result in improved fasting blood glucose. Interestingly, after 6months, HIF-
fed mice had decreased basal AMPK activation in liver and skeletal muscle tissue (P < .05).
Basal glucose metabolism was changed by SMSC supplementation as evidenced by
increased fasting blood glucose and glucose intolerance. High dietary IF levels did not
protect against aberrant blood glucose. In FVB mice, decreased basal AMPK activation is not
the mechanism through which Se exerts its effect. These results suggest that more research
must be done to elucidate the role of Se and IF in glucose metabolism.
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Adenosine monophosphate–activated protein kinase (AMPK)
has been characterized as a master regulator of the cellular
energy state, and it is known to regulate both lipid and glucose
metabolism. Adenosine monophosphate–activated protein
kinase is activated in response to changes in high-energy
phosphate concentrations through its AMP- and adenosine
diphosphate–sensing domains. In general terms, activation of
AMPK results in the inhibition of adenosine triphosphate
consuming processes such as lipogenesis and protein synthe-
sis and the activation of processes important for adenosine
triphosphate synthesis such as β oxidation and glucose uptake
(See review [1]).
Current efforts are underway to find effective activators of
AMPK as a treatment for diseases associated with insulin
resistance (IR), such as type II diabetes. The commonly
prescribed diabetes drug metformin, for example, is a well
characterized activator of AMPK [2]. In addition to pharmaco-
logic agents, certain dietary factors may potentiate or inhibit
AMPK signaling. Understanding the impact of different
nutrients or dietary supplements on AMPK signaling and
glucose control is important for long-term maintenance of
healthy glucose and lipid metabolism.
Selenium (Se) is an essential micronutrient, which plays an
important role in redox reactions, especially in enzymes such
as glutathione peroxidase and thioredoxin reductase [3].
Research on Se supplementation has supported its chemo-
preventive efficacy to be substantial for prostate cancer [4–9].
Interestingly, supplementation of inorganic Se compounds
has also been shown to alter glucose metabolism [10] in
preclinical models. The effects of Se on glucose metabolism
depend on the form of dose administered. For example, 2
inorganic forms of Se, selenate and selenite, affect glucose
management in opposite ways. Selenate decreases IR [10,11]
and in some ways can be considered an insulin mimetic [12].
Alternatively, selenite seems to interfere with insulin signal-
ing [13], contributing to increased IR. Although effects of high
doses of inorganic forms of Se are clearly demonstrated in
these and similar studies, the relevance to human glucose
metabolism is uncertain.
Inorganic Se compounds account for only a small frac-
tion of total Se naturally occurring in foods. Far more abun-
dant are organic compounds such as selenomethionine and
Se-methylselenocysteine (SMSC). In the Selenium and
Vitamin E Cancer Prevention Trial (SELECT), a high dose of
selenomethionine was given to subjects, most of whom
began the study with high Se status [14]. Such supplemen-
tation resulted in a minimal but statistically significant
increase in risk of type II diabetes [14]. The choice of SMSC for
use in this study is based on (a) its significant contribution to
total Se in foods, particularly in those foods of high total Se
content; (b) its high biological availability; (c) its demon-
strated ability to induce selenoenzyme activity and increase
other markers of Se status; (d) chemopreventive efficacy,
which is superior to that of selenomethionine; (e) its low
toxicity in comparison with other Se forms; (f) its nonin-
volvement in protein synthesis, unlike selenomethionine,
which is incorporated nonspecifically into proteins in placeof methionine and thus diverted from Se metabolic path-
ways; and (g) the paucity of data concerning effects on
glucose metabolism of this Se form, which is demonstrably
relevant and significant in human nutrition. Elucidating the
mechanisms throughwhich supplemental Se affects glucose
metabolism, particularly forms of Se that are commonly
found in food, is an important step in understanding the
associated risk of Se supplementation. Recent work by Misu
et al [15] has shown that Se-induced changes in glucose
metabolismmay occur by reducing basal activation of AMPK.
If Se is to be useful as an anticancer supplement without
increasing the risk of metabolic diseases associated with IR,
it may be necessary to couple it with other factors that limit
these potential complications.
Isoflavones (IF) are estrogen-like compounds found primar-
ily in soy. Increased dietary IF cause favorable adaptations in
glucose metabolism [16]. Interestingly, there is growing evi-
dence that these changesmaybe facilitatedvia increasedAMPK
activation [17]. Isoflavones are also reported to cause a
reduction inbody fat that is likelymediated by increased energy
metabolism [18]. Thus, increasing IF consumption may be an
effective approach to help prevent or limit the potentially
negative impact of Se supplementation on glucose manage-
ment. Therefore, due to differences in metabolic responses to
increased IF and Se, we hypothesized that (1) a chronic increase
in SMSC consumption would lead to impaired glucose control,
(2) a high IF (HIF) diet would improve glucose control, and (3) if
HIF diet was consumedwith high SMSC, the negative effects on
glucose management associated with Se supplementation
would be attenuated. Furthermore, we sought to determine if
supplemental SMSC alone, increased IF consumption, or the
combination of the 2 approaches had an impact on basal AMPK
activation in skeletal muscle and liver tissue.2. Methods and materials
2.1. Animal care
All experimental procedures used were approved by the Institu-
tional Animal Care Committee of Brigham Young University.
MaleFVBmicewereassigned to1of 2 experimentaldiets (Table 1)
and given either supplemental SMSC orwater for 6months. Mice
werehoused ina temperatureand light controlled room(12hours
0600-1800, light) andwere given free access to food anddeionized
water. Body weights were recorded 3 times per week.
2.2. Diets
Custom diets were designed to provide either minimal IF
content (low IF [LIF]) as the control diet or a diet that provided
a high concentration of IF (HIF) (500 mg/kg of genistein +
daidzein aglycone equivalents) from soybean meal. The
soybean meal used in TD.10126 (HIF) was tested for IF, and
the sum of genistein + daidzein was 2700 mg/kg (aglycone
form). The same lot of soybean meal was used for multiple
production of the diet during the course of the experiment.
Soybean meal and corn gluten meal in the respective diets
contributed equivalent amounts of protein. Specific amino acids
weresupplemented toprovideabalancedaminoacidpatternand
Table 1 – Ingredient composition of Teklad custom
research diets a
Ingredient (g/kg diet) LIF HIF
Corn gluten meal (60%) 153.0 –
Soybean meal (48%) – 190.0
Corn 304.5 277.5
Wheat 220.0 220.0
Wheat middlings 220.0 220.0
DL-methionine, Feed Grade (FG) (99%) – 1.5
L-leucine – 8.0
Soybean oil 35.0 35.0
Brewer’s yeast, dried, FG 10.0 10.0
Mineral Mix, Global Rodent (98217) 5.0 5.0
Calcium phosphate, dibasic 3.4 7.5
Calcium carbonate 18.5 14.5
Sodium chloride, iodized 5.0 5.0
Vitamin Mix, Global Rodent (98218) 5.0 5.0
Choline chloride, FG (60%) 1.8 1.0
Potassium phosphate, dibasic 7.5 –
L-lysine HCl, FG (98.5%) 5.8 –
L-arginine HCl 4.5 –
L-tryptophan 1.0 –
Total 1000.0 1000.0
a Diets were matched for macronutrient composition and energy
content (18% protein, 6% fat, 45% carbohydrate by weight, and 12.98 kj).
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diets. Diets were matched for macronutrient and micronutrient
composition (Table 1). Mice were fed either a high (HIF) (Teklad,
TD. 10126; Harlan, Teklad, Madison, WI, USA) or minimal (LIF)
(Teklad, TD. 10127; Harlan) IF diet ad libitum (Table 1).
Supplemental Se was administered orally by pipette to
provide 3mg Se/kg bodyweight daily from a 14mg/mL solution
of SMSC (300640010; Acros, Geel, Belgium Organics) in double-
deionized water or water placebo. Se-methylselenocysteine is
metabolized by β-lyase tomethylselenol and enters a pool,where
it can be used in a variety of pathways, including selenoprotein
synthesis. This form of Se has shown cancer chemopreventive
properties [19].
2.3. Blood collection
All withdrawals came from the tail vein. Before drawing blood
for fasting glucose, mice were fasted for 8 hours. Lidocaine gel
was applied liberally before incision and wiped off with sterile
tissue paper immediately before to prevent sample contam-
ination. Blood samples were taken (50 uL) after 24 hours of
fasting for insulin assay.
2.4. Blood Se measurements
As a measure of Se status, total Se in serum samples was
determined using the modified Association of Official Analyt-
ical Chemists (AOAC) fluorometric method of Koh and Benson
[20], as we previously described [21].
2.5. Tissue collection and processing
Mice were anesthetized with 0.6 mg/g body weight sodium
pentobarbital via intraperitoneal injection. Tissue collectionbeganoncemicewerecompletely sedated.Tissueswere removed
quickly and snap frozen in liquid nitrogen–cooled metal tongs
thenwrapped inaluminumfoil andstoredat−80○C.Aftermuscle
dissections and blood collection, epididymal, mesenteric, retro-
peritoneal, and brown adipose fat pads were taken and weighed
before being frozen in liquid nitrogen and stored at −80○C.
Frozenmusclewasweighed and homogenized in lysis buffer
(50 mmol/L Tris HCl, 250 mmol/L mannitol, 50 mmol/L Sodium
Fluoride (NaF), 5 mmol/L sodium pyrophosphate, 1 mmol/L
EDTA, 1 mmol/L ethylene glycol tetra acetic acid (EGTA), 1%
Triton X-100, 50 mmol/L β-glycerophosphate, 1 mmol/L sodium
orthovanadate, 1 mmol/L Dithiothreitol (DTT), 1 mmol/L benza-
midine, 0.1 mmol/L phenylmethanesulfonylfluoride (PMSF),
5 μg/mL soybean trypsin inhibitor, and1 μg/mL of aprotinin,
leupeptin, and pepstatin, pH 7.4). Homogenate was stored
at −80°C.
2.7. Western blot analysis
The homogenized samples were frozen to −80°C and thawed 3
times to ensure complete membrane lysis. Samples were then
spun down at 1000g for 10 minutes, the supernatant was
collected, and protein concentration was determined by the
bicinchoninic acid (BCA) method. Protein samples for electro-
phoresis were made using the Laemmli method. Proteins were
separated byweight on SodiumDodecyl Sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) gels. The gels were transferred
to nitrocellulose or polyvinylidene difluoride (PVDF) mem-
branes and incubated in 5% (wt/vol) milk or body surface area–
blocking solution for 1 to 1.5 hours. The membranes were then
incubated in primary antibody at 4°C overnight or at room
temperature for 1 hour. After a series of Tris-buffered saline
with tween-20 (TBST) washes, the membranes were incubated
in secondary antibody suspended in a 1% (wt/vol) milk or body
surface area–TBST solution for 1 hour. After the final washes,
ECL (GE Healthcare, Cardiff, UK) was applied to cover the
membrane. Membranes were then developed using autoradio-
graphic film, and results were quantified using National
Institutes of Health Bethesda, MD, USA software. Antibodies
used in this study include the following: AMPK (2532 L; Cell
Signaling, Beverly, MA, USA), phosphorylated AMPK (pAMPK)
(4188 L; Cell Signaling), acetyl-CoA carboxylase (ACC) (3662; Cell
Signaling), phosphorylated ACC (3661S; Cell Signaling), liver
kinase B1 (LKB1) (no. 07-694; LKB1, Charlottesville, VA, USA),
uncoupling protein 3 (UCP3) (AB3046; Millipore, Temecula, CA,
USA), Cytochrome c (Cyt C) (C5723; Sigma-Aldrich, USA), and
glucose transporter type 4 (GLUT4) (2213; Cell Signaling).
2.8. Statistical analyses
A power analysis was performed to determine the estimated
number of animals that would be necessary to determine
differences between groups. An SD estimated approximately 10%
to 15% of the mean with difference of 25% considered a
physiologically meaningful difference (α, .05; power of 0.7-0.8).
A 2×2 factorial design was used (Table 1). Data are presented as
mean±SE.All statisticalanalyseswereperformedusingSigmaStat,
San Jose, CA, USA 3.5 software. Two-way analysis of variance was
performedwith Bonferroni post hoc test. Significancewas defined
as P < .05.
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Fig. 1 – Glucose tolerance AUC. Intraperitoneal GTT results. Mice
were injectedwitha20%glucosesolution,andbloodglucosewas
measured at 0, 15, 30, 60, and 120minutes. Graph represents
mean±SE for groups thatdidnot receive supplemental Se (black)
and those that did receive 3 mg Se/kg per day as SMSC (gray).
Therewasa tendency for amain effect for increasedAUC (P= .08)
in mice given supplemental SMSC. Data are shown asmeans ±
SE (minute [milligrams per deciliter]), n = 6 to 10.
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3.1. Serum Se, body weight, and fasting blood glucose
There was a main effect of SMSC supplementation on
increasing serum Se concentration (P < .001). When the
interaction with HIF and SMSC supplementation was exam-
ined, HIF Se group was showing higher levels than the LIF Se
group (P < .05). There were no differences in initial weight,
weight gain, final weight, or abdominal fat accumulation
(Table 2). There was a main effect of supplemental SMSC
on increasing fasting blood glucose (P < .05) (Table 2). Within the
HIF groups, SMSC caused a significant increase in fasting blood
glucose (P < .05), and within the LIF groups, a trendwas apparentTable 2 – Bodyweight, growth rate, abdominal fat, fasting blood
diets with or without accompanying Se supplementation
LIF
Control
Initial body weight (g) 20.6 ± 0.4
Growth rate (g/wk) 0.5 ± 0.04
Final body weight (g) 32.3 ± 1.2
Total abdominal fat (g) 2.5 ± 0.2
Fasting blood glucose (mg/dL) 106.8 ± 6.1
μg Se/mL serum 1.8 ± 0.1
Data are mean ± SE.
Significance was defined as P < .05, n = 5 to 7.
a Indicates a main effect of SMSC supplementation.
b Indicates that there was a significant difference for the HIF SMSC group
SMSC.
c Indicates a significant difference between LIF + SMSC and HIF + SMSC.for the effect of SMSC (P = .075). Fasting insulin levels were not
different between groups (data not shown).
3.2. Glucose tolerance
Supplementing mice with 3 mg/kg SMSC did not result in a
significant difference in the response to a glucose challenge as
determined by the area under the curve (AUC) for the glucose
tolerance test (GTT); however, a trend was apparent (main
effect of SMSC, P = .08) (Fig. 1). This trend for increased IR is
consistent with the impaired fasting blood glucose in these
animals (Table 2). The glucose tolerance pattern observed in
the absence of increased dietary IF also tended to be higher
with supplemental SMSC (P = .08), whereas no such effect was
apparent in the animals consuming high IF (Fig. 1).
3.3. AMPK pathway
Basal AMPK activation was determined via immunoblot for
pAMPK in muscle and liver samples. Surprisingly, the HIF diet
had a main effect of decreased AMPK phosphorylation in red
quadriceps (RQ) (Fig. 2B) and white quadriceps (WQ) (Fig. 2A)
and tibialis anterior (TA) muscles (Fig. 2C). The basal level of
pAMPK in the liver remained unchanged in all groups (Fig. 2D).
To investigate AMPK activation in muscle more thoroughly,
we also measured the protein expression of the upstream
kinase LKB1 (Fig. 3) and the downstream target of AMPK, ACC
in the same tissues (Fig. 4). A main effect for decreased LKB1
protein in theHIF groupswas consistentwith decreasedAMPK
phosphorylation in the RQ (Fig. 3C) and mixed fiber-type TA
muscle (Fig. 3B). Moreover, in both the TA and the RQmuscles,
where we observed reduced AMPK phosphorylation and LKB1
content, there were no significant differences or trends for
reduced ACC phosphorylation (Fig. 4B and C).
3.4. Mitochondrial content
As both Cyt C and UCP3 are markers of mitochondrial content
and AMPK is known to affect mitochondrial content, we
measured protein expression via immunoblot to further
investigatemetabolic response to SMSC and IF. No differencesglucose, and serumSe levels ofmale FVBmice fed LIF or HIF
HIF
SMSC Control SMSC
21.0 ± 0.7 21.0 ± 0.8 21.8 ± 0.4
0.5 ± 0.02 0.5 ± 0.02 0.5 ± 0.01
32.1 ± 0.9 31.7 ± 1.1 33.4 ± 0.5
2.6 ± 0.3 2.4 ± 0.2 2.7 ± 0.2
118.5 ± 3.5 a 106.2 ± 2.8 121.6 ± 2.8 a,b
4.9 ± 0.4 a 1.9 ± 0.2 6.1 ± 0.6 a,c
compared with the corresponding control group that did not receive
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Fig. 2 – Basal phosphorylation of AMPK in skeletal muscle and liver. In the 3 muscles examined (WQ [A], RQ [B], and TA [C]),
there was a main effect of dietary IF content on AMPK phosphorylation (P < .05). We did not observe an effect of either SMSC
supplementation or IF content of the diet in liver tissue (D). The representative blots are presented in the same order (left to
right) as the groups in the figure. Graph represents mean ± SE for groups that did not receive supplemental SMSC (black) and
those that did receive 3mg Se/kg per day as SMSC (gray). Line and asterisk indicate amain effect of IF decreasing pAMPK levels
in WQ, P < .05; RQ, P < .05; and TA, P < .05; n = 4 to 9.
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(Fig. 5A, C, and E) or UCP3 (Fig. 5B, D, and F).
3.5. GLUT4 protein levels
We investigated changes in total GLUT4 protein expression in
the WQ, TA, and RQ muscles. Despite increased fasting
glucose and a trend for reduced glucose tolerance in mice
given SMSC, GLUT4 protein levels were unchanged compared
with mice that received dietary IF alone (Fig. 6A-C).4. Discussion
The primary focus of this study was to examine the impact of
SMSC supplementation with or without HIF intake on basal
glucose management. Based on previous work and available
information from human studies, we hypothesized that (1)SMSC would have a negative impact on basal glucose
management and (2) increasing the dietary content of IF
would attenuate this effect. To our knowledge, our study is the
first to examine blood glucose changes with chronic supple-
mentation of a common food form of Se. Our results support
our hypothesis that high Se intake or status negatively
impacts basal blood glucose management. Contrary to our
hypothesis and previous reports demonstrating a positive
effect of an HIF diet on glucose management, we found that
HIF intake did not attenuate the increased fasting blood
glucose that resulted from SMSC supplementation. Interest-
ingly, although not statistically significant, there was a
tendency for improved glucose tolerance in animals that
were given both elevated SMSC and HIF compared with SMSC
alone. Furthermore, both Se and IF have been reported to
affect AMPK activation and thus cause changes in glucose
management. Contrary to our original hypothesis, we did not
observe a change in basal AMPK activation with SMSC
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Fig. 3 – Liver kinase B1 protein expression in white, mixed,
and red skeletal muscle. In TA (B) (P < .01) and RQ (C) (P < .05),
there was a main effect of the HIF diet of decreasing LKB1
protein levels. This effect was not observed in the WQ
(A). The representative blots are presented in the same order
(left to right) as the groups in the figure. Graph represents
mean ± SE for groups that did not receive supplemental
SMSC (black) and those that did receive 3mg Se/kg per day as
SMSC (gray). Line and asterisk indicate a main effect of IF
decreasing LKB1, n = 6 to 9.
Fig. 4 –Acetyl-CoA carboxylase phosphorylation inwhite,mixed,
andredskeletalmuscle. In themuscles tested (WQ[A],TA [B], and
RQ [C]), neither SMSCnorHIF intake alteredACCphosphorylation
asmeasured byWestern blot despite increased phosphorylation
of its upstream kinase AMPK. All data are presented as
phosphorylated ACC/ACC, and the representative blots are
presented in the same order (left to right) as the groups in the
figure.Graph representsmean±SE for groups thatdidnot receive
supplemental SMSC (black) and those that did receive 3mgSe/kg
per day as SMSC (gray), n = 5 to 7.
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increased dietary IF.
Selenium is an essential component of enzymes critical to
antioxidant defense. Although the precise mechanisms are
not completely understood, high Se intake or status has beenreported to reduce the risk of developing prostate and other
cancers. However, in contrast to its chemopreventive effects,
high Se intake or status may also have a negative impact on
blood glucose management. The effect that supplemental Se
has on blood glucose is clearly dependent on the chemical
Fig. 6 – Glucose transporter type 4 in white, mixed, and red
skeletal muscle. Glucose transporter type 4 is the
insulin-sensitive glucose transporter inskeletalmuscle.Despite
Se-induced tendency for increased AUC in GTTs, total GLUT4
protein levels were unchanged in theWQ (A), TA (B), and RQ
(C)muscles. Representative blots are presented in the sameorder
(left to right) as the groups in the figure. Graph representsmean ±
SE for groups that did not receive supplemental SMSC (black) and
those thatdid receive3mgSe/kgperdayasSMSC (gray),n=4 to5.
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with SMSC, an organic form of Se that is abundant in foods
high in Se and has a high bioavailability. Although our results
contrast with those seen from increased intake of sodium
selenate [10,11], our findings are consistent with observation-
al studies that have found a correlation between increased
serum Se and increased incidence of type 2 diabetes [23,24]. A
small increase in the risk of developing type 2 diabetes was
also found after supplementation of selenomethionine in the
large, randomized, controlled SELECT [14]. In addition to the
results of the SELECT trial, the randomized, controlled trial
reported by Stranges et al showed a significant increase in the
incidence of type 2 diabetes resulting from supplementation
of 200 μg Se daily in a high-Se brewer’s yeast tablet, which
provides Se in multiple chemical forms [24]. However, in that
study, the increased risk from Se supplementation was
confined to those in the highest tertile of baseline plasma Se
(>121.6 ng/mL). Those who began the study with lower plasma
Se concentration experienced no increase in risk for T2D from
consuming high-Se yeast.
The mechanisms by which increased dietary IF improve
glucose management are not clear. Cederroth et al [17] have
reported that increased IF cause increased activation of AMPK
in peripheral tissues. As noted above, one of the proposed
mechanisms by which elevated Se negatively impacts insulin
sensitivity is by reducing AMPK activation [15]. This prompted
us to explorewhether increased IF consumptionwould reduce
the negative effects of high Se on blood glucose. Accordingly,
we examined AMPK activation by (1) measuring the basal
phosphorylation of AMPK, (2) measuring the protein expres-
sion of the primary regulator of AMPK in skeletal muscle and
liver tissue (LKB1), and (3) examining downstream targets
(ACC phosphorylation) and effects of chronic AMPK activation
(GLUT4, Cyt C, and UCP3 protein expression [25–27]). Surpris-
ingly, SMSC supplementation did not decrease AMPK phos-
phorylation but HIF intake did in all 3 of the different skeletal
muscle types that we examined. Consistent with this pattern,
in 2 of the muscles, we observed a similar reduction in the
expression of the upstream regulator of AMPK, LKB1. Skeletal
muscle is the tissue that accounts for the largest amount of
glucose uptake from the blood in response to a glucose
challenge. These results, along with a lack of improvement in
fasting blood glucose with increased IF do not support this
dietary intervention as an effective approach to improve
insulin sensitivity and overall glucose management.
Another mechanism by which increased IF may affect
overall glucose management is via a reduction in body fat
accumulation. Previous work from our group and others has
reported that increased IF intake reduces body fat accumula-
tion [18,28,29]. This reduction in body weight, in at least one
report [18], was accompanied by an increase in thermogene-
sis. This response could be related to increased AMPK
activation. In our study, we did not observe any significant
difference or trend for changes in abdominal fat accumulation
or body weight. It is important to note that the animal model
used in our study (FVB mice) was different from that used in
related studies. In addition, we used custom diets specifically
designed to control for IF levels. Although the source of a
portion of the protein was different between the diets, the 2
diets had almost equivalent ingredient composition, similar
316 N U T R I T I O N R E S E A R C H 3 4 ( 2 0 1 4 ) 3 0 8 – 3 1 7amino acid profiles, andwerematched for vitamins, minerals,
and energy content. This is in contrast to other diet pairs
described in the literature [17,18,29], where similar end points
were measured.
If the improvement in glucose management that has been
reported previously was secondary to decreased adiposity,
then we would not expect to see metabolic benefits in our
model. It is understood that different strains of mice are more
susceptible to developing IR and even diabetes using treat-
ments that alter fat accumulation [30–32]. Because of the fact
that we did not observe any significant metabolic benefits of
increased IF intake, we suspect that some of the proposed
benefits of increased IF intake that have previously been
reported are due to decreased body fat.
Limitations of the overall impact of our findings include
first, the apparent strain-dependent nature of our findings;
second, the relatively small sample size for some of our
comparisons; and third, the moderate nature of our dietary
protocol. The mouse model that we chose to use in this
study was simply based on the fact that FVB mice are a
very commonly used mouse model used in research. We
were not attempting to select a strain that would be more
or less susceptible to diet-induced obesity or IR. Recent
work by Montgomery et al examined strain-dependent
variations in obesity and glucose management, including
the FVB mouse strain as well as 4 other commonly used
mouse models [30]. Their results do not suggest that the
FVB mouse strain is unusually susceptible or resistant to
diet-induced obesity or IR. Thus, the apparent strain-
dependent differences of increased IF intake that we
observed compared with previous studies are something
that need further investigation.
The second potential limitation of our study concerns the
somewhat small sample size used in some of the comparisons
thatweremade.Althoughapower analysiswasperformedwith
anticipated variability, we experienced somewhat more vari-
ability than what was expected for some of our measures. One
comparison that deserves attention is the GTT. Our analysis
revealed a tendency for improved glucose tolerancewithhigh IF
andSMSC intakecomparedwithhighSMSC intakealone.Witha
greater sample size, this comparison may yield a significant
benefit of increased IF intake on glucose management consis-
tentwithour original hypothesis. However, this extrapolation is
difficult to support when the entirety of our findings with
respect to high IF intake is considered. Firstly, we did not
observe an effect of IF on the impaired fasting glucose induced
by SMSC intake. Second, the basal AMPK activation or signaling
was not elevated with increased IF (in fact, impaired AMPK
activation was observed with IF in several tissues). Lastly,
increased IF in our animal model did not cause a reduction in
body fat accumulation as others have reported.
Another potential limitation of our study concerns the
modest nature of our dietary protocol. Our study was not
performed using a diet that would be expected to cause
metabolic stress known to lead to IR. The value of our findings
certainly apply to a baseline effect of increased SMSC or IF
intake on glucose management and AMPK signaling. We fully
expect that future studies examining the impact of SMSC and/
or IF intake in the context of a high-fat diet may yield different
results that would expand on the work we present here.In summary, the purpose of our study was to examine the
effects of supplemental SMSC and/or dietary IF on basal
glucose regulation and AMPK activation. Certain forms of Se
have shown deleterious effects on blood glucose, whereas IF
have reportedly shown potential insulin-sensitizing proper-
ties. Based on work done by others, we hypothesized that
SMSC, an organic source of Se abundant in food, would result
in impaired glucose regulation, and dietary IF would amelio-
rate SMSC-induced aberrations. Our results are consistent
with our hypothesis that SMSC contributes to glucose
dysregulation as we observed a tendency for glucose intoler-
ance and a significant increase in fasting blood glucose in the
SMSC group. However, our results do not support our
hypothesis that HIF would be an effective approach to
ameliorate effects of SMSC on blood glucose management or
AMPK activation. Furthermore, our HIF diet had no effect on
body weight or abdominal fat accumulation and caused a
reduction in AMPK activation in our model.Acknowledgment
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